Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy.

  “Endocannabinoids are now emerging as suppressors of key cell-signaling pathways involved in cancer cell growth, invasion, and metastasis. We have previously observed that the metabolically stable anandamide analog, 2-methyl-2′-F-anandamide (Met-F-AEA) can inhibit the growth of thyroid cancer in vivo. Our hypothesis was that the anti-tumor effect observed could be at least in part ascribed to inhibition of neo-angiogenesis… our results suggest that anandamide could be involved in the control of cancer growth targeting both tumor cell proliferation and the angiogenic stimulation of the vasculature.”

http://www.ncbi.nlm.nih.gov/pubmed/17192847

Leave a Reply

Your email address will not be published. Required fields are marked *